Business Wire

GLOBAL-DAIRY-PLATFORM

11.11.2022 01:02:43 CET | Business Wire | Press release

Share
Dairy Sector Reports Progress on Global Pathways to Dairy Net Zero Climate Initiative at COP27

The dairy sector today announced progress of its global Pathways to Dairy Net Zero (P2DNZ) climate initiative, which was launched last year. The ground-breaking effort is achieving positive results in many regions and accelerating action in others, according to speakers at a COP27 side event, “The Global Dairy Sector’s Climate Ambition and Progress Towards Achievement of the Paris Agreement.”

P2DNZ is backed by more than 140 leading organizations and governments, including the 10 largest dairy companies in the world. Collectively, supporters represent more than 40% of global dairy production throughout the supply chain, making it one of the largest initiatives of its kind in agriculture.

“Dairy is a major force for good in the world, especially when you consider how the sector helps provide important nutrition to the hungry and malnourished and helps build strong, resilient economies, said Hein Schumacher, chair of Global Dairy Platform, one of the founders of Pathways to Dairy Net Zero, and CEO of Royal FrieslandCampina. “By systematically introducing and enhancing climate action in global dairy systems, dairy is tackling the challenge and making progress in reducing our impact on the planet,” he said.

Research is Identifying Practical Pathways for Dairy Systems Worldwide
Research commissioned as part of P2DNZ has identified six primary dairy production systems throughout the world, along with potential mitigation options and their estimated impact on emissions reduction. The research is led by the Global Research Alliance on Agricultural Greenhouse Gases (GRA) in close collaboration with the UN Food and Agriculture Organization (FAO). They have defined the composition of GHGs emitted by the various dairy production systems around the world and learned there is variability by system. For instance, methane is a large proportion of GHGs in pastoral and agropastoral systems, driven largely by enteric fermentation. However, high-input, high-output production emits a different mix of GHGs from not only enteric fermentation but also manure management, animal feed and energy use.

The six dairy production systems include:

  • High-input, high-output
  • Medium-scale specialized
  • Pasture-fed
  • Smallholder specialized
  • Smallholder dual-purpose
  • Pastoral and agropastoral

Researchers are also modeling the impact on warming of cumulative emissions for each GHG. This work is critical because each gas has a different effect and unique longevity in the atmosphere. For instance, while methane is a highly potent GHG it breaks down in the atmosphere in 12 years. Whereas other gases, such as carbon dioxide, can remain in the atmosphere for hundreds of years.

Although mitigation options will vary by each dairy production system, some of the primary pathways include improving animal health, increasing feed digestibility, enhanced manure storage and treatment, more efficient fertilizer use and the potential adoption of methane-inhibiting feed additives.

“Because GRA brings together leading expertise in agricultural GHG emissions, we are pleased to be working on the Pathways to Dairy Net Zero initiative to map emissions and mitigation potential within the diverse range of global dairy production systems,” said Dr. Harry Clark, co-chair of the Livestock Research Group of GRA and co-director of the New Zealand Agricultural Greenhouse Gas Research Centre. “While there are good options emerging for dairy systems in developed countries, our analysis reinforces the importance of developing and implementing appropriate options for regions and systems where the climate, soil and access to markets have limited options,” he said.

Progress in Developed Markets
Dairy companies around the world are reducing their impacts on the environment by improving farming and production practices and developing new technologies. FAO reports that during the period from 2005 – 2015, the global dairy sector’s emission intensity declined by 11%. Dairy farming has become more efficient which is resulting in declining emission intensities per unit of product all over the world. This is especially true in developed dairy markets where emission intensities have declined to between 1.3 to 1.4 kg CO₂ equivalent kg fat-and-protein corrected milk. For comparison, developing dairy regions’ emission intensities can range between 4.1 to 6.7 kg CO₂ equivalent per kg fat-and-protein corrected milk.

Tackling Emissions in Emerging Markets
Many of the best practices that have already been developed are being implemented in emerging dairy countries, where approximately 80% of the global dairy sector’s emissions are generated.

To help facilitate and accelerate these efforts, the global dairy sector, the Global Methane Pledge, FAO and others have invited 10 developing dairy countries to join P2DNZ as “early adopters.” Collectively these countries represent more than 30% of the sector’s global GHG emissions and include (those in bold have already accepted):

  • Africa: Tanzania, Kenya, Rwanda, Uganda
  • Americas: Uruguay, Costa Rica, Colombia
  • Asia: Pakistan, Vietnam, India

For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.

###

About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.

Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.

The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005906/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye